Role of PD‐L1 Expression in Non‐Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. Methods: 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of CD274 (PD-L1) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). Results: PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (p < 0.0001) and in higher lymph node status (pN) (p = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (p = 0.0332) in adenocarcinoma (AC) only. Conclusions: PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, anti‐PD‐1/PD‐L1 antibodies can promote T cell activation and enhance anti‐tumor immunity by blocking the interaction between PD‐1 and PD‐L1/PD‐L2 [270, 271].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some tumors express PD‐L1, which contributes to immune evasion by inhibiting cytotoxic responses.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“The estimation of PD-L1 expression was performed using the Tumor Proportion Score (TPS) that is applied routinely in diagnostic settings [4,27,28].”
MethodLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“According to the American Cancer Society, the number of deaths from lung cancer is higher than the number of deaths caused by breast, colon and prostate cancers [1].”
BackgroundRemmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · cited 1×
“The first effect is inhibition of interleukin 2 (IL-2) synthesis [8].”
BackgroundProgrammed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755 · cited 1×
“In our cohort, involving a Western population, the incidence was lower, which is similar to other studies on this ethnic group [12,16,24] Another explanation for diverse expression of PD-L1 in NSCLC may be related to the use of different scoring methods and cut-off levels for evaluation.”
ResultKonishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Cited by
Items 101–192 of 192
Huang, D., Wang, X., Qian, Y., Wu, J., Chen, B., Zhang, D., Dong, F., & Li, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104706 · Cited by 7
PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment
Shahin, M., Patra, S., Purkait, S., Kar, M., Majumdar, S. K. D., Mishra, T. S., Samal, S. C., & Nayak, H. K. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01049-z · Cited by 7
Ahmed, E., Shanmugasundaram, K. B., Li, J., Behren, A., Lobb, R. J., Möller, A., Wuethrich, A., Dey, S., Sina, A. A. I., & Trau, M. (2023) · Advanced Sensor Research · doi:10.1002/adsr.202300059 · Cited by 7
Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients.
Zhu, Q., Zhang, J., Xu, D., & Zhao, R. (2023) · PubMed Central · Cited by 6
Yuan, Y., Mishra, F., Li, B., Peng, G., Chan, P., Yang, J. J., & Liu, Z. (2024) · Cancers · doi:10.3390/cancers16132483 · Cited by 6
“Lung cancer is often believed to be more immunogenic with high levels of PDL-1 expression in tumors [1,2].”
BackgroundImmune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
Li, W. J., Najdawi, W. O., Badla, O., Galor, A., & Karp, C. L. (2025) · Seminars in Ophthalmology · doi:10.1080/08820538.2025.2458658 · Cited by 7
High tumor burden in non-small-cell lung cancer: A review of the literature
Cabezón‐Gutiérrez, L., Sereno, M., Cervera, R., Mielgo-Rubio, X., & Higuera, O. (2022) · Journal of Clinical and Translational Research · doi:10.18053/jctres.08.202205.008 · Cited by 9
“More recently, PD-L1 expression has been studied in patients with NSCLC and it seems to be associated with greater tumor proliferation and aggressiveness with higher Ki-67, higher histological grade, greater lymphatic involvement (pN), and worse OS [34,35].”
BackgroundResearch landscape and trends of melanoma immunotherapy: A bibliometric analysis
Liu, Y., Yu, L., Liang, Y., Cheng, X., Jiang, S., Yu, H., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024179 · Cited by 7
“By breaking the interactions, CTLA-4/PD-1/PD-L1 blockades up-regulate T-cell activity and strengthen anti-tumor immune response (34).”
BackgroundIsmail, L., Zahid, K., Polyanskaya, A., Othman, A. A., Shen, N., Qi, X., Sulimanov, R. A., Esakov, Y., Makarov, V. A., Filkov, G. I., et al. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_233_24 · Cited by 6
Arthofer, E., Chakraborty, K., Viney, L., Johnson, M. J., Webber, B. R., Moriarity, B. S., Lou, E., Choudhry, M. S., Klebanoff, C. A., & Henley, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.17.456714 · Cited by 7
Shanmugiah, J., Kim, S., Jeong, H., Kong, J. S., Lee, S.-S., Kang, D. K., & Kim, J. S. (2026) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2026.141897 · Cited by 7
Helmy, D. O., Khattab, F., Hegazy, A. E., & Sabry, R. M. (2022) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2022.2137810 · Cited by 6
Kilaru, S., Panda, S. S., Moharana, L., Mohapatra, D., Mohapatra, S. S. G., Panda, A. K., Kolluri, S., Devaraj, S., & Biswas, G. (2024) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-024-00207-5 · Cited by 5
“Our cohort of stage IV NSCLC showed a higher percentage of PD-L1 positivity when compared to similar real-world studies involving stage IV NSCLC patients by Yan Jin et al. [15] and Pawelczyk et al. [16].”
ResultLiu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01361-z · Cited by 9
Zheng, Y., Chen, L., Liu, X., Li, R., Lei, H.-B., & Chen, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428307 · Cited by 6
Moradi, S., Sarikhani, P., Albadr, R. J., Taher, W. M., Alwan, M., Jawad, M. J., Mushtaq, H., & Vakilzadehian, N. (2025) · Discover Oncology · doi:10.1007/s12672-025-02076-3 · Cited by 6
“Higher levels of PD-L1 expression in NSCLC cells were associated with higher lymph node status and higher malignancy rate in addition to shorter patient survival, mainly in the adenocarcinoma (AC) group [69].”
Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy
Chern, B., Pinto, D., Lum, H. Y. J., & Parameswaran, R. (2024) · Biomedicines · doi:10.3390/biomedicines12061304 · Cited by 7
“Studies in some human cancers have shown that tumour necrosis correlates with PD-L1 expression and indicate an aggressive phenotype with a poor prognosis [57,58], possibly due to the upregulation of hypoxia-inducible factor-1 α 67 and tumour necrosis-α [59,60].”
BackgroundMachine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC
Yu, D., Kane, M. J., Koay, E. J., Wistuba, I. I., & Hobbs, B. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-64977-7 · Cited by 8
“%) experience shorter survival times 16–19 .”
Brar, K., Taslimi, S., Ellenbogen, Y., Deng, J., Hou, W., de Moraes, F. Y., Glantz, M., Zacharia, B. E., Tan, A. C., Ahluwalia, M. S., et al. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.10.113 · Cited by 5
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series
Fernández‐Trujillo, L., García-Robledo, J. E., Zúñiga-Restrepo, V., & Sua, L. F. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101114 · Cited by 6
Puglisi, M. M., May, L., Gardiyehewa, T., & Landry, J. W. (2025) · Cancers · doi:10.3390/cancers17243953 · Cited by 4
“In addition, there is an association with high PD-L1 expression and decreased length of survival in NSCLC, especially in patients with adenocarcinoma [32].”
InfluentialOhhara, Y., Kojima, T., Honjo, O., Yamada, N., Sato, T., Takahashi, H., Takamura, K., Takashina, T., Sukoh, N., Tanaka, H., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae168 · Cited by 4
Sarova, P., Mosleh, B. O., Zehetmayer, S., Oberndorfer, F., Widder, J., Prosch, H., Aigner, C., Idzko, M., Hoda, M. A., & Gompelmann, D. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15336 · Cited by 5
Prognostic impact of nectin-like molecule-5 (CD155) expression in non-small cell lung cancer
Popa-Navarro, X., Avilés‐Salas, A., Hernández‐Pedro, N., Orozco‐Morales, M., Caballé‐Perez, E., Castillo-Ruiz, C., Lucio-Lozada, J., Barrios‐Bernal, P., Hernandez‐Martinez, J., & Arrieta, O. G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05471-6 · Cited by 4
Bi̇lgi̇n, B., Hızal, M., YÜCEL, Ş., Şendur, M. A. N., Akyürek, N., Akıncı, M. B., Yılmaz, Ü., & Yalçın, B. (2020) · Tuberkuloz ve Toraks · doi:10.5578/tt.69182 · Cited by 4
“Additionally, the Ki-67 proliferation index was found low positively correlated with PD-L1 expression (17).”
BackgroundLi, Y., Li, C., Jiang, Y., Han, X., Liu, S., Xu, X., Tang, W., Ou, Q., Bao, H., Wu, X., et al. (2022) · Journal of Oncology · doi:10.1155/2022/1763778 · Cited by 7
“Previous study observed an association of PD-L1 high expression with smoking status [48, 49] which may be related to the alteration of tumor microenvironment by smoking [9], whereas no smoking data was available in our study which may be regarded as an issue of the real-world data [50, 51].”
BackgroundPD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer
Gurevičienė, G., Matulionė, J., Poškienė, L., Miliauskas, S., & Žemaitis, M. (2024) · Medicina · doi:10.3390/medicina60030482 · Cited by 4
“On the other hand, other studies did not show statistically significant differences between the stage of NSCLC and PD-L1 expression, hence the results remain controversial [55].”
ResultVinh‐Hung, V., Gorobets, O., Duerinkcx, A., Dutta, S., Oboite, E., Oboite, J., Ali, A., Mazibuko, T., Karlsson, U., Chi, A., et al. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-821 · Cited by 4
“The prevalence of tumors with a high TPS score ranged from 10.5% to 31% for locally advanced NSCLC (18-27).”
InfluentialTherachiyil, L., Surendranath, A., Anand, A., Sahin, R. D., Akil, A. S. A.-S., Bhat, A. A., & Shahab Uddin, M. S. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00949 · Cited by 4
He, Y., Zhang, W., Guo, Z., Yu, W., Zhao, W., Li, Y., Chen, Z., Li, Y., Xu, K., Zhang, Q., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf565 · Cited by 3
“Recent research has identified that PD-L1 expression levels, tumor immunity within the microenvironment, antigen loss through immunoediting, defects in tumor antigen presentation, and metabolic alterations are all closely correlated with the efficacy of immunotherapy in lung cancer [17 ,18 ].”
Ganesh, S., Wang, R., & Chen, H. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2021.018610 · Cited by 4
Role of immunotherapy in metastatic EGFRm NSCLC: Is it relevant?
Dhabhar, B. N., Sahoo, T. P., & Akshay, J. K. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_49_21 · Cited by 3
Zhang, D., Gao, X., Yan, Z., He, W., & Li, Q. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02035-2 · Cited by 3
“PD-L1 is highly expressed in the tissues of patients with advanced lung cancer (with lymph node metastasis, TNM III-IV), which is consistent with previous studies [12, 13] and also provides an objective basis for the”
ResultMwanzi, S., Sayed, S., Das, S., Wawire, J., Njenga, P., Shah, J., & Shaikh, A. J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102348 · Cited by 3
Franks, K., Smith, D., Shaw, P., Banna, G. L., Cominos, M., Talbot, T., Blak, B. T., Lindqvist-Brown, L., & Ahmed, M. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103949 · Cited by 3
Wutti‐in, Y., Luangwattananun, P., Sawasdee, N., Vongchan, P., Yenchitsomanus, P., & Panya, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118967 · Cited by 4
Kumar, S., Pandey, M., Mir, I. A., Mukhopadhyay, A., Sharawat, S. K., Jain, D., Saikia, J., Malik, P. S., Kumar, S., & Mohan, A. (2021) · Human Cell · doi:10.1007/s13577-021-00647-4 · Cited by 2
Jain, P., Chauhan, N. K., Chakraborti, A., Gupta, M. K., Dutt, N., Jalandra, R. N., Elhence, P. A., Rao, M., Khera, P. S., Garg, P. K., et al. (2023) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2023.01.001 · Cited by 2
Naga Naveena, N., Mohanty, S., Das, S. N., Rath, R., & Narayanan, S. P. (2024) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13584 · Cited by 2
Krpina, K., Mavrinac, M., Samarzija, M., Tolić, E., Darapi, D., & Batičić, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226695 · Cited by 2
Gupta, A., Chandra, S., Chauhan, N., & Arora, A. (2022) · Journal of Laboratory Physicians · doi:10.1055/s-0042-1757232 · Cited by 3
Dhawan, V., Chandra, S., Kala, M., & Khanduri, S. (2022) · Journal of Laboratory Physicians · doi:10.1055/s-0042-1758665 · Cited by 2
García-Herreros, L. G., Rico-Rivera, E. X., & Morales, O. M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226820 · Cited by 1
Anoop, T. M., Raj, L., Nair, P., & Vincent, A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf168 · Cited by 3
Alsavaf, M. B., Issa, M., Klamer, B. G., Husain, M., Dibs, K. N., Pan, X. J., Grecula, J. C., Old, M. O., Konieczkowski, D. J., Mitchell, D., et al. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14135 · Cited by 3
Jacob, S. (2020) · Turkish Journal of Pathology · doi:10.5146/tjpath.2021.01525 · Cited by 2
“Tumor cells express programmed death ligand -1 (PD-L1) to produce an immunosuppressive milieu in the local tissue microenvironment for evading immunity as one of the modes of survival and this is associated with an aggressive course (1-3).”
BackgroundThe Role of Programmed Cell Death Receptor 1 in Lung Cancer
Badiu, D. C., Zgura, A. F., Mehedințu, C., Hăineală, B., Anghel, R. M., & Bacinschi, X. E. (2022) · In Vivo · doi:10.21873/invivo.12794 · Cited by 1
Kanthali, M., Mamgain, P., Dhawan, P., Bhagwat, G., Patel, S., & Purohit, M. R. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.6.1855
“There are limited and controversial data on PD-L1 expression in EGFR -mutated lung adenocarcinoma (Inamura et al., 2016; Rangachari et al., 2017; Yang et al., 2014; Song et al., 2016; Pawelczyk et al., 2019).”
BackgroundFigueiredo, M. I., de Sousa, V. M. L., & Carvalho, L. (2021) · Research Square · doi:10.21203/rs.3.rs-1135697/v1 · Cited by 1
An overview on precision therapy in bladder cancer
Sayed, A., Munir, M., Eweis, N., Wael, D., Shazly, O., Awad, A. K., Elbadawy, M. A., & Eissa, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1801346
Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung CancerPreprint
Ebelt, N., Zuniga, E., Marzagalli, M., Zamloot, V., Blazar, B., Salgia, R., & Manuel, E. R. (2020) · bioRxiv · doi:10.1101/2020.10.09.332387
“Antibody-mediated inhibition of the PD-1/PD-L1 axis is a promising new treatment option for non-small cell lung cancer (NSCLC), which continues to be the leading cause of cancer-related death in the United States and worldwide [8-10].”
BackgroundInfluentialPharmacogenomics of Anti-Cancer Drugs
Carr, D. F., Turner, R. M., & Pirmohamed, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00159-6
The genomic landscape of lung adenocarcinoma—insights towards personalized medicine
Kour, O., & Garg, M. (2021) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-021-00054-1 · Cited by 2
“Checkpoint inhibitors can reactivate the antitumor immunity delay tumor growth and lengthen the survival by blocking this pathway (Konrad et al. 2019).”
BackgroundZhou, J., Lin, H., Ni, Z., Luo, R., Feng, M., & Zhang, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4098972
Suganuma, H., Kusumoto, S., Manabe, R., Kishino, Y., Endo, T., Andō, K., Ishida, H., Horiike, A., Tanaka, A., Takei, H., et al. (2022) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.34.64
Mehdizadeh‐Shrifi, A., Redwan, B., & Golpon, H. A. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100203
MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer
Klimenko, O. V., & Sidorov, A. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_53
Ganie, F., Mehfooz, N., Siraj, F., Khan, U. H., Mantoo, S., Dhar, A., Mir, M. H., Jan, R. A., Shah, S., & Qadri, S. M. (2023) · Cureus · doi:10.7759/cureus.35056
“[13], which found positive PD-L1 expression in 32.”
BackgroundXiong, L. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5579
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2752985/v1
Alföldi, R. (2022) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11231
Mani, S., Lakshmanan, A., & Subramanyan, A. (2023) · Apollo Medicine · doi:10.4103/am.am_133_23
“[4] B7-H1, binds to its receptors programmed death-1 (PD-1) and B7-1.”
BackgroundInfluentialImpact of SARS-CoV-2 on lung cancer patient under immunotherapy
Mondonga, R. L., Fănică, A.-A., Gurzu, I. E., & Mihaltan, F. D. (2022) · Pneumologia · doi:10.2478/pneum-2023-0027
Molecular testing in lung cancer
Shiau, C. J., & Tsao, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00023-7 · Cited by 1
Pirinççi, E., Oruç, Z., Ebinç, S., Güzel, Y., Kömek, H., Küçüköner, M., Urakçı, Z., Ma, K., Taşdemir, B., & Işıkdoğan, A. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.97451
Wang, T., Fan, Z., Yue, Y., Lü, X., Deng, X., & Hou, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3530547/v1
Li, R., Zhang, H., Zhao, Y., Li, Y., Yao, X., Dong, X., Xu, Y., & Li, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3949359/v1
Bittar, H. E. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-50977-3_1
Overview of Molecular Diagnostics in Irish Clinical Oncology
Medina, T. D., Hynes, S. O., Lowery, M. A., Gillespie, P., Kölch, W., & Seoighe, C. (2024) · HRB Open Research · doi:10.12688/hrbopenres.13822.1
PD-L1 Immunoexpression on Cytology and its Paired Comparison with Histopathology in Lung Carcinoma
Chandra, S., Dhawan, V., & Kediya, A. (2023) · Annals of Pathology and Laboratory Medicine · doi:10.21276/apalm.3279
The role of tumor-associated neutrophils in early luminal HER2-negative breast cancer progression
Антонович, Б. З., Титов, К. С., Zakurdaev, E. I., Lorie, Z. V., Chizhikov, N. P., & Kharina, D. V. (2024) · Russian Journal of Oncology · doi:10.17816/onco624111
Александрович, М. А., Аксарин, А. А., Микичович, П. А., Петрович, Т. П., & Иванович, П. А. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-3-115-123
Kim, S.-Y., Park, D., Sun, P., Kim, N., Lee, D., Kim, D. K., Lee, S., Lee, J. E., Chung, C., & Kang, D. H. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-392 · Cited by 2
Mehta, A. A., P, L., Teja, L., & Pillai, K. (2024) · Cureus · doi:10.7759/cureus.72291
Sureka, N., Arora, S., Ish, P., & Khanna, G. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3288
Overview of Molecular Diagnostics in Irish Clinical Oncology
Medina, T. D., Hynes, S. O., Lowery, M. A., Gillespie, P. R., Kölch, W., & Seoighe, C. (2025) · HRB Open Research · doi:10.12688/hrbopenres.13822.2
Arif, M., Prakash, V., Kumar, H., Shukla, S., Tripathi, A., Singh, M., Kumar, S., & Verma, A. K. (2025) · Annals of African Medicine · doi:10.4103/aam.aam_147_25
Fekry, M. A. H. M., El-Gohary, Y., Abdel‐Aziz, H. R., Hassan, T. H., & Ahmed, M. M. (2025) · Cytopathology · doi:10.1111/cyt.70037
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679881
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679875
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679878
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679872
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679866
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679884
Liu, W., Tang, T., Feng, J., Wang, C., Lin, L., Wang, S., Zeng, K., Zou, R., Yang, Z., & Zhao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26679869
Memmos, N., Kaveh, K., Webber, B. R., Moriarity, B. S., & Odde, D. J. (2026) · Physical Biology · doi:10.1088/1478-3975/ae4705
Mikaeel, B. Y., Othman, G. Q., Salihi, A. B., Awla, F., Jalil, O., Beyaz, S., Demirelli, Ş., & Aslan, A. N. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2627195
“…of the study was to compare the level of PDL1 ligand expression and localization in NSCLC to that of commonly used diagnostic markers such as Ki-67 proliferation antigen, p63, and thyroid transcription factor 1 (TTF-1) proteins, which are used to differentiate morphologic subtypes of NSCLC (29).”
Hybrid Modeling of Currency Circulation Volatility: Evidence from the Central Bank of Iraq
Akram, A. T., & Ali, D. O. (2026) · Statistics Optimization & Information Computing · doi:10.19139/soic-2310-5070-3279
Impact de la radiothérapie interne vectorisée alpha sur le microenvironnement tumoral
Perrin, J. (2021) · theses.fr (ABES) · doi:10.70675/31c91866z101fz4e07zbde2z6887a8fdba6d
Hussain, S. H. (2023) · theses.fr (ABES) · doi:10.70675/a049ec43z2b82z4851zbbc3z95e504507ac2 · Cited by 2
Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies
Kim, A. M. J., Lee, N., Chen, H., & Lim, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108404
“Such overexpression has been documented across non-small cell lung cancer (NSCLC) [32], melanoma [33], head and neck squamous cell carcinoma (HNSCC) [34]. bladder or urothelial carcinoma [35]. triple-negative breast cancer [36], renal cell carcinoma (RCC) [37]. and ovarian cancer [38]. among many…”
Efthymiadis, K., Soteriou, C., Kotoula, V., Papadopoulou, K., Pouliakis, A., Lampaki, S., GOUSSIA, A. C., Fountzilas, E., Meditskou, S., Bobos, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198724
“In complete case multivariable logistic regression ( n = 245), high tumour grade (G3–4) was the sole independent predictor of PD-L1 positivity (adjusted OR 2.08, 95% CI: 1.08–4.19; p = 0.033), a finding which is consistent with existing literature [47,48].”
Influential
Metadata
- Authors
- Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K.
- Affiliations
- Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland
- Wroclaw Medical University (PL)
- Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-14
- Volume
- 20
- Issue
- 4
- Pages
- 824
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6413136
- OpenAlex
- W2913496992
- Cited by
- 192
- References
- 50
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 39 · 2023: 29 · 2022: 35 · 2021: 37 · 2020: 22 · 2019: 6
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (ST.A110.17.037)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- PD-L1, non-small cell lung cancer, prognostic factors, tumor grade, lymph node metastasis, overall survival, lung adenocarcinoma, Ki-67, p63, TTF-1, PD-1/PD-L1 immune checkpoint, tumor cell proliferation
- MeSH terms
- Thyroid Nuclear Factor 1, Adenocarcinoma, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Membrane Proteins, Middle Aged, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Ki-67 Antigen, Tissue Array Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.